[go: up one dir, main page]

NO20080403L - Nanoparticulate megestrol formulations - Google Patents

Nanoparticulate megestrol formulations

Info

Publication number
NO20080403L
NO20080403L NO20080403A NO20080403A NO20080403L NO 20080403 L NO20080403 L NO 20080403L NO 20080403 A NO20080403 A NO 20080403A NO 20080403 A NO20080403 A NO 20080403A NO 20080403 L NO20080403 L NO 20080403L
Authority
NO
Norway
Prior art keywords
nanoparticulate megestrol
megestrol formulations
formulations
megestrol
nanoparticulate
Prior art date
Application number
NO20080403A
Other languages
Norwegian (no)
Inventor
Tuula Ryde
Douglas Hovey
John Pruitt
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20080403L publication Critical patent/NO20080403L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives nanopartikkel preparater omfattende megestrol. Megestrol partiklene i preparatet har en midlere effektiv partikkelstørrelse på mindre enn rundt 2000 nm.Nanoparticle preparations comprising megestrol are described. Megestrol particles in the composition have an average effective particle size of less than about 2000 nm.

NO20080403A 2005-06-22 2008-01-21 Nanoparticulate megestrol formulations NO20080403L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69312705P 2005-06-22 2005-06-22
PCT/US2006/024349 WO2007002315A2 (en) 2005-06-22 2006-06-22 Nanoparticulate megestrol formulations

Publications (1)

Publication Number Publication Date
NO20080403L true NO20080403L (en) 2008-03-19

Family

ID=37595838

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080403A NO20080403L (en) 2005-06-22 2008-01-21 Nanoparticulate megestrol formulations

Country Status (13)

Country Link
EP (1) EP1901713A2 (en)
JP (1) JP2008546796A (en)
KR (1) KR20080024213A (en)
CN (1) CN101242810A (en)
AU (1) AU2006262144A1 (en)
BR (1) BRPI0612665A2 (en)
CA (1) CA2613466A1 (en)
EA (1) EA200800099A1 (en)
IL (1) IL188322A0 (en)
MX (1) MX2008000396A (en)
NO (1) NO20080403L (en)
WO (1) WO2007002315A2 (en)
ZA (1) ZA200800376B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147605B (en) * 2015-06-24 2019-04-19 中国人民解放军军事医学科学院毒物药物研究所 Progesterone nanocomposite and preparation method thereof
CN105687027A (en) * 2016-01-26 2016-06-22 中国科学院生物物理研究所 A non-alcoholic amino acid type rinse-free foam lotion
CN105769763A (en) * 2016-05-25 2016-07-20 西安德天药业股份有限公司 Megestrol acetate nanosuspension and preparation method and application thereof
CN108309933A (en) * 2018-03-19 2018-07-24 青岛国海生物制药有限公司 A kind of oral megestrol acetate nanosuspension and preparation method thereof
CN108409821A (en) * 2018-03-19 2018-08-17 青岛国海生物制药有限公司 A kind of preparation method and megestrol acetate of megestrol acetate nanocrystal
CN112891309B (en) * 2019-11-19 2022-07-26 北京化工大学 Megestrol acetate nano dry suspension and preparation method thereof
CN111643463A (en) * 2020-07-08 2020-09-11 西安远大德天药业股份有限公司 Megestrol acetate dispersible tablet and preparation method thereof
CN111930838B (en) * 2020-07-23 2023-05-16 金陵科技学院 A Time-Oriented Distributed File Management Method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227626B (en) * 1988-11-28 1991-04-23 Vectorpharma Int SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003230885A1 (en) * 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
ES2366646T3 (en) * 2003-11-05 2011-10-24 Elan Pharma International Limited COMPOSITIONS IN THE FORM OF NANOPARTICLES THAT HAVE A PEPTIDE AS A SURFACE STABILIZER.

Also Published As

Publication number Publication date
MX2008000396A (en) 2009-02-23
EP1901713A2 (en) 2008-03-26
WO2007002315A3 (en) 2007-04-05
CN101242810A (en) 2008-08-13
JP2008546796A (en) 2008-12-25
IL188322A0 (en) 2008-04-13
KR20080024213A (en) 2008-03-17
CA2613466A1 (en) 2007-01-04
BRPI0612665A2 (en) 2010-11-30
WO2007002315A2 (en) 2007-01-04
EA200800099A1 (en) 2008-06-30
AU2006262144A1 (en) 2007-01-04
ZA200800376B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20073559L (en) Nanoparticulate tacrolimus formulations
NO20080403L (en) Nanoparticulate megestrol formulations
DE60325718D1 (en) Nystatin NANOPARTICLE COMPOSITIONS
EA200701997A1 (en) COMPOSITION OF BISPHOSPHONATE NANOPARTICLES
ATE431131T1 (en) MELOXICAN FORMULATIONS IN NANOPARTICLE FORM
ATE457718T1 (en) STERILE FILTERED NANOPARTICLE FORMULATIONS OF BUDESONIDE WITH TYLOXAPOL AS SURFACE STABILIZER
ATE415946T1 (en) NEW METAXALONE COMPOSITIONS
DE602004012117D1 (en) NEW COMPOSITIONS OF SILDENAFIL-FREE BASE
UY38044A (en) SOLID PHARMACEUTICAL COMPOSITIONS INCLUDING PHENOFIBRATE IN NANOPARTICLES
ATE343376T1 (en) NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
EA200701442A1 (en) COMPOSITIONS OF KANDESARTANA NANOPARTICLES
IL269619B (en) Preparations of sulfoalkyl other than cyclodextrin and methods for their preparation
EA200702638A1 (en) STABLE COMPOSITION (RECIPE) WITH ACETAMINOPHEN NANOPARTICLES
MX336930B (en) Ganaxolone formulations and methods for the making and use thereof.
CY1113036T1 (en) PHARMACEUTICAL FORMS OF MAXESTROL NANOSPHERE
ATE385777T1 (en) NANOPARTICLE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS
MX343209B (en) Oral care composition.
ATE371442T1 (en) COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE PROPERTIES
MX2010009866A (en) Nanoparticulate compositions of angiogenesis inhibitors.
ATE422155T1 (en) NANOPARTICLE COMPOSITIONS CONTAINING FENOFIBRATE
MX2010007498A (en) Visibly transparent uv photoprotective compositions.
EP1952919A3 (en) Magnetic nanoparticles and aqueous colloid composition containing the same
WO2006138421A3 (en) Nanoparticulate azelnidipine formulations
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
ATE446742T1 (en) NANOPARTICULAR EBASTIN FORMULATIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application